mani
hurdl
remain
develop
global
deploy
vaccin
elicit
durabl
immun
respons
prevent
infect
diseas
like
requir
use
adjuv
immun
present
usa
two
licens
adjuv
although
adjuv
vaccin
licens
part
world
mani
test
human
anim
trial
review
highlight
recent
work
adjuv
develop
vaccin
particular
emphasi
antibodi
respons
word
adjuv
deriv
french
adjuv
deriv
latin
adjuv
translat
helper
term
first
use
modern
vaccin
context
gaston
ramon
institut
pasteur
seri
paper
eg
establish
use
adjuv
elicit
hightit
antitoxin
respons
sinc
time
mani
compound
formul
test
abil
adjuv
vaccin
respons
develop
new
adjuv
parallel
increas
understand
pattern
recognit
receptor
prr
role
recruit
direct
immun
system
adjuv
compound
formul
prepar
deliveri
system
enhanc
modifi
immunogen
primari
antigen
vaccin
adjuv
perform
function
varieti
way
nearli
involv
trigger
prr
stimul
innat
adapt
arm
immun
system
accomplish
one
two
way
incorpor
activ
compound
vaccin
formul
eg
formul
protein
immunogen
liposom
contain
agonist
incorpor
element
vaccin
result
product
immun
stimul
eg
addit
plasmid
express
cytokin
dna
vaccin
regimen
distinct
absolut
formul
incorpor
element
approach
develop
adjuv
acceler
last
year
degre
parallel
develop
vaccin
candid
time
number
excel
review
publish
reader
may
find
use
review
focu
histor
context
adjuv
develop
sinc
discoveri
recent
develop
final
highlight
lack
compar
data
current
avail
shortli
discoveri
secretari
health
human
servic
margaret
heckler
held
press
confer
predict
vaccin
trial
would
possibl
within
year
first
vaccin
trial
began
follow
seri
attempt
develop
effect
vaccin
earli
vaccin
studi
focus
leverag
strategi
success
vaccin
includ
viru
inactiv
subunit
immunogen
along
novel
strategi
recombin
viral
construct
although
earli
subunit
vaccin
candid
immunogen
none
followup
efficaci
trial
show
protect
concurr
develop
vaccin
candid
numer
anim
human
studi
compar
avail
adjuv
headtohead
trial
clearli
superior
regimen
identifi
like
lack
consist
immunogen
across
trial
along
differ
immun
scheme
differ
outcom
measur
exampl
mannhalt
et
al
report
immun
chimpanze
recombin
envelop
env
use
alum
waterinoil
emuls
term
lipidbas
adjuv
alum
plu
deoxychol
tcell
respons
best
lipidbas
adjuv
shown
last
month
final
immun
antibodi
respons
report
niedrig
et
al
report
anoth
group
chimpanze
immun
formaldehydeinactiv
adjuv
alum
freund
incomplet
adjuv
oilinwat
emuls
zinc
hydroxidelecithinbas
adjuv
studi
antibodi
titer
best
lecithinbas
adjuv
although
prolifer
antibodydepend
cellmedi
cytotox
adcc
respons
similar
lecithin
alum
arm
levi
et
al
report
comparison
rabbit
alum
iscom
iscomatrix
muramyl
dipeptid
mdp
freund
complet
adjuv
recombin
immunogen
antibodi
titer
highest
freund
complet
adjuv
mdp
time
period
numer
mous
studi
publish
nearli
demonstr
one
adjuv
superior
headtohead
studi
vaccin
shown
tabl
vaccin
candid
deem
promis
advanc
phase
phase
ii
human
trial
studi
test
protein
peptid
recombin
poxviru
vector
although
none
candid
produc
overwhelm
immun
vaccin
gener
safe
well
toler
without
stronger
candid
avail
controversi
decis
made
pursu
phase
iii
trial
poxviru
boost
vaccin
strategi
propos
detractor
support
ultim
demonstr
modest
shortliv
degre
efficaci
adjuv
use
trial
alum
us
food
drug
administr
fda
approv
adjuv
time
studi
consid
examin
immun
regimen
use
potent
adjuv
see
whether
protect
enhanc
prolong
remaind
review
address
recent
develop
adjuv
research
dna
vaccin
attract
elicit
tcell
respons
protein
product
antigen
process
occur
without
need
infecti
vector
dna
vaccin
gener
potent
elicit
antibodi
respons
although
evid
suggest
dna
vaccin
prime
subsequ
protein
boost
numer
studi
report
abil
immun
modul
provid
adjuv
effect
dna
vaccin
studi
perform
mice
compar
one
regimen
unadjuv
control
studi
wide
varieti
adjuv
test
vaccin
recent
compar
data
limit
univers
adjuv
adjuv
must
select
base
desir
respons
care
pair
immunogen
test
heterolog
adjuv
strategi
may
need
balanc
efficaci
sideeffect
compar
avail
dnaencod
adjuv
smallerscal
studi
report
exampl
test
seri
dna
adjuv
mice
suggest
one
test
adjuv
superior
eg
granulocytemacrophag
coloni
stimul
factor
gmcsf
studi
primat
show
modest
benefit
work
ongo
absenc
systemat
studi
present
clear
whether
dnaencod
adjuv
superior
elicit
desir
immun
vaccin
studi
examin
effect
ad
compound
dna
vaccin
without
encod
vector
mycobacteri
extract
shown
enhanc
tcell
antibodi
respons
mice
agonist
liposom
mannan
deliveri
vehicl
dna
vaccin
enhanc
fecal
iga
respons
alter
subclass
respons
mice
anoth
tolllik
receptor
tlr
agonist
imiquimod
appli
topic
adjuv
dna
vaccin
mice
although
effect
similar
gmcsf
dnaencod
adjuv
molecul
unclear
strategi
superior
recent
studi
suggest
physic
adjuv
may
benefici
dna
vaccin
electr
current
adjuv
test
mice
rhesu
macaqu
human
result
suggest
electropor
alon
effect
dnaencod
adjuv
although
sideeffect
higher
electropor
group
electropor
almost
certainli
act
increas
uptak
vaccin
dna
cell
minor
tissu
damag
stimul
damageassoci
prr
recruit
inflammatori
respons
test
need
determin
whether
electropor
implement
reduc
sideeffect
yet
remain
effect
immun
stimulatori
molecul
encod
viral
bacteri
vector
suffici
room
genom
eg
poxvirus
mycobacteria
dna
vaccin
studi
test
differ
adjuv
mix
result
poxviru
vector
cytokin
solubl
ligand
test
mice
enhanc
immun
respons
compar
control
similar
strategi
test
viral
vector
eg
rhabdoviru
adjuv
also
ad
vector
encod
exampl
solubl
ligand
ad
dnaprimepoxvirusboost
strategi
enhanc
tcell
respons
though
effect
antibodi
variabl
remain
seen
strategi
ultim
prove
use
human
trial
whether
adjuv
formul
enhanc
recombin
vector
investig
naito
et
al
demonstr
mous
model
tether
liposom
poxviru
vector
overcam
previou
immun
could
stimul
humor
cellular
immun
mani
adjuv
oilinwat
emuls
disrupt
lipid
membran
would
consid
inappropri
envelop
replic
vector
like
poxvirus
addit
replic
vector
stimul
immun
system
transient
infect
caus
clear
adjuv
transient
present
site
inject
would
use
futur
studi
need
clarifi
question
vaccin
studi
greatest
varieti
adjuv
test
subunitrecombin
protein
immunogen
note
larg
number
headtohead
trial
perform
prior
tabl
sinc
time
largescal
direct
comparison
publish
older
adjuv
continu
explor
defin
paramet
critic
efficaci
alum
one
commonli
employ
adjuv
long
histori
use
human
rel
eas
regulatori
approv
reason
research
optim
util
ongo
hansen
et
al
show
abil
alum
adsorb
env
protein
import
immunogen
bind
tightli
reduc
immun
respons
immun
dorosko
et
al
show
altern
method
deliv
alum
direct
immun
respons
inject
alumbas
peptid
immunogen
region
supramammari
lymph
node
goat
result
antibodi
secret
colostrum
novel
adjuv
continu
studi
anim
model
lipidbas
adjuv
like
seri
shown
stimul
strong
antibodi
respons
guinea
pig
although
respons
similar
elicit
oilinwat
emuls
adjuv
one
adjuv
seri
elicit
hightit
antibodi
rhesu
macaqu
also
use
human
clinic
trial
wherein
gener
antibodi
tcell
respons
anoth
adjuv
seri
also
elicit
immun
respons
human
adjuv
seri
best
vaccin
yet
establish
oilinwat
emuls
adjuv
use
mani
year
includ
miner
oilbas
formul
eg
freund
adjuv
modern
squalenebas
prepar
also
prove
use
platform
explor
addit
immun
stimul
compound
tlr
agonist
like
cpg
oligodeoxynucleotid
mix
squalenebas
adjuv
appear
enhanc
adjuv
effect
addit
carbopol
enhanc
immunogen
rabbit
level
compar
complet
freund
adjuv
like
slower
releas
immunogen
recent
report
combin
tlr
ligand
differ
squalenebas
oilinwat
emuls
stimul
higher
titer
antibodi
greater
breadth
function
respons
combin
agonist
optim
rhesu
macaqu
adjuv
formul
studi
well
liposom
formul
modifi
polyethylen
glycol
elicit
durabl
antibodi
respons
env
peptid
propos
mechan
persist
modifi
liposom
lead
prolong
immun
respons
compound
deriv
pathogen
also
shown
promis
initi
studi
protein
deriv
worm
onchocerca
volvulu
enhanc
antibodi
respons
mice
multipl
human
trial
env
protein
immunogen
combin
differ
adjuv
formul
tabl
unfortun
compar
data
lack
especi
headtohead
comparison
adjuv
use
immunogen
dose
schedul
use
adjuv
human
demonstr
promis
exampl
adjuv
formul
env
immunogen
abl
elicit
similar
titer
antibodi
despit
differ
high
low
immunogen
dose
group
suggest
adjuv
might
dosespar
effect
addit
studi
need
determin
best
adjuvantimmunogen
combin
futur
largescal
trial
elicit
mucos
respons
cholera
toxin
ct
bacteri
product
extens
test
anim
model
ct
combin
env
elicit
mucos
iga
rhesu
macaqu
studi
rhesu
albeit
differ
form
ct
elicit
mix
respons
ct
also
use
direct
respons
mucosa
combin
agent
enhanc
retent
mucos
surfac
permit
dose
spare
addit
modifi
ct
combin
cytokin
abl
elicit
mucos
antibodi
peptid
immunogen
given
cynomolgu
monkey
suggest
promis
combin
identifi
vaccin
strategi
eg
dna
vaccin
might
use
mucos
immun
mucos
strategi
investig
interestingli
intranas
cytokin
appear
effect
ct
elicit
mucos
antibodi
mice
soybean
oil
nanoemuls
deliv
intranas
env
elicit
iga
respons
bacteri
product
like
mycoplasmaderiv
lipopeptid
shown
adjuv
vaccin
mice
cranag
et
al
demonstr
env
administ
carbopol
intravagin
result
better
mucos
respons
system
immun
mice
thymic
stromal
lymphopoietin
shown
elicit
mucos
antibodi
level
similar
ct
final
strategi
employ
microneedl
combin
agonist
abl
elicit
strong
antibodi
respons
includ
vagin
iga
mice
possibl
success
vaccin
strategi
may
involv
heterolog
immun
use
alvacprimeaidsvaxboost
trial
strategi
continu
investig
anim
model
regimen
contain
peptid
adjuv
imiquimod
oilinwat
emuls
abl
prime
viral
vector
boost
rhesu
macaqu
elicit
strong
tcell
modest
antibodi
respons
similarli
alphavirusbas
particul
vaccin
prime
combin
protein
boost
use
rhesu
macaqu
result
better
respons
also
somewhat
protect
infecti
challeng
sideeffect
consider
may
also
drive
heterolog
primeboost
regimen
studi
rabbit
use
oilinwat
emuls
prime
alum
boost
show
antibodi
respons
highest
mix
regimen
author
suggest
regimen
could
use
overcom
undesir
side
effect
strongli
adjuv
vaccin
use
less
reactiv
adjuv
subsequ
step
edelman
tacket
aptli
state
best
adjuv
never
correct
choic
wrong
epitop
aid
vaccin
field
identifi
best
immunogen
work
continu
find
strategi
elicit
durabl
broad
protect
infect
work
find
optim
adjuv
strategi
continu
parallel
effort
present
data
drive
ration
choic
adjuv
aid
vaccin
lack
partli
lack
robust
immunogen
also
pauciti
compar
data
publish
last
decad
headtohead
comparison
adjuv
formul
use
immunogen
report
especi
compar
first
year
aid
pandem
tabl
partial
reason
adjuv
licens
part
licensur
vaccin
product
entir
appropri
regulatori
hurdl
mean
adjuv
licens
track
licensur
combin
vaccin
nonhiv
pathogen
could
put
risk
adjuv
found
superior
vaccin
candid
definit
adjuv
inferior
vaccin
mean
adjuv
inferior
vaccin
inferior
vaccin
would
render
licens
vaccin
ineffect
howev
would
creat
percept
one
compani
adjuv
better
other
put
vaccin
use
inferior
adjuv
risk
given
vaccin
market
small
compar
blockbust
drug
compani
appear
appropri
reluct
put
invest
risk
addit
hurdl
face
adjuv
develop
prevent
measur
vaccin
well
toler
gener
popul
ideal
caus
sideeffect
anyon
vaccin
requir
stimul
immun
system
establish
balanc
stimul
sideeffect
paramount
fig
howev
medic
intervent
without
risk
like
success
vaccin
caus
degre
sideeffect
recipi
import
determin
level
accept
risk
balanc
vaccin
efficaci
public
judgment
accept
risk
depend
vaccin
efficaci
highli
effect
vaccin
present
threat
sideeffect
like
accept
vaccin
less
effect
pathogen
perceiv
less
threat
effect
vaccin
avail
work
find
better
adjuv
continu
wide
varieti
adjuv
formul
avail
enhanc
respons
immunogen
excit
new
work
suggest
formul
better
balanc
safeti
efficaci
may
possibl
howev
much
work
remain
determin
optim
adjuv
immunogen
combin
effect
control
aid
pandem
view
express
mam
entir
necessarili
reflect
duke
univers
us
govern
conflict
interest
mam
support
center
hivaid
vaccin
immunologyimmunogen
discoveri
grant
chaviid
grant
conflict
interest
paper
particular
interest
publish
within
annual
period
review
highlight
immun
stimul
system
inflamm
safeti
fewer
side
effect
figur
adjuv
activ
balanc
adjuv
need
well
toler
effect
abil
stimul
immun
respons
often
associ
side
effect
investig
need
determin
whether
efficaci
achiev
low
sideeffect
profil
degre
inflamm
necessari
